DDInter1191 DDInter782
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Methylprednisolone {u} (Compound) resembles {v} (Compound) Halobetasol Propionate
Methylprednisolone {u} (Compound) resembles {v} (Compound) Testolactone
Methylprednisolone {u} (Compound) treats {v} (Disease) rheumatoid arthritis
Methylprednisolone {u} (Compound) binds {v} (Gene) CYP3A4
Methylprednisolone {u} (Compound) upregulates {v} (Gene) ZFP36
Methylprednisolone {u} (Compound) palliates {v} (Disease) hematologic cancer
Methylprednisolone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Methylprednisolone {u} (Compound) downregulates {v} (Gene) FOSL1
Methylprednisolone {u} (Compound) causes {v} (Side Effect) Diplegia
Methylprednisolone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Methylprednisolone (Compound) resembles Halobetasol Propionate (Compound)
Methylprednisolone (Compound) resembles Testolactone (Compound)
Methylprednisolone (Compound) treats rheumatoid arthritis (Disease)
Methylprednisolone (Compound) binds CYP3A4 (Gene)
Methylprednisolone (Compound) upregulates ZFP36 (Gene)
Methylprednisolone (Compound) palliates hematologic cancer (Disease)
Methylprednisolone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Methylprednisolone (Compound) downregulates FOSL1 (Gene)
Methylprednisolone (Compound) causes Diplegia (Side Effect)
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid